ArticleAnnals of pediatric endocrinology & metabolism2026
Bisphosphonate therapy for thalassemia-related bone disorders in children and young adults: a systematic review.
Article in Annals of pediatric endocrinology & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skeletal complications represent a major morbidity in transfusion-dependent thalassemia (TDT), particularly among children and young adults. Osteopenia and osteoporosis arise from marrow expansion, iron overload, endocrine dysfunction, and vitamin D deficiency, leading to impaired bone mass accrual. Although bisphosphonates are widely used in osteoporosis, their role in thalassemia has not been systematically appraised. This review aims to evaluate the role of bisphosphonates in pediatric and young adult patients with TDT-related bone disorders. A systematic search of PubMed/MEDLINE, Scopus, Cochrane Library, ProQuest, and gray literature was conducted from inception to August 2025. Eligible studies included randomized, nonrandomized, and prospective observational trials evaluating bisphosphonates in patients ≤25 years with TDT-related osteopenia or osteoporosis. Primary outcomes were changes in lumbar spine and hip bone mineral density (BMD). Secondary outcomes included biochemical markers, bone pain, fracture incidence, and safety. The review followed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) 2020 guidelines and was registered in PROSPERO (CRD420251138498). Eleven nonrandomized prospective studies involving over 300 participants were included. Six studies evaluated pamidronate, 3 zoledronate, and 2 alendronate. Pamidronate generally improved lumbar spine and hip BMD, with more consistent gains when combined with calcium/vitamin D. Zoledronate was associated with BMD improvement but required pediatric-adjusted dosing to avoid hypocalcemia. Alendronate improved BMD z-scores and reduced bone pain in adolescents. Across studies, bisphosphonates lowered bone turnover markers and were generally well tolerated. Bisphosphonates may improve bone density and alleviate pain in TDT-related bone disease. Larger randomized controlled trials are required to determine long-term efficacy, fracture outcomes, and optimal treatment regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.